Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: A meta-analysis
Background: In recent years, several clinical trials have focused on oncolytic virus (OVs) combined with chemotherapy or immune checkpoint inhibitors (ICIs) in solid tumor patients, which showed encouraging effects. However, few studies have concentrated on the summary on the safety and efficacy of...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-11-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.1023533/full |
| _version_ | 1798015302502449152 |
|---|---|
| author | Xiangxing Liu Jiaojiao Zhang Keqing Feng Simin Wang Liming Chen Suping Niu Qian Lu Yi Fang |
| author_facet | Xiangxing Liu Jiaojiao Zhang Keqing Feng Simin Wang Liming Chen Suping Niu Qian Lu Yi Fang |
| author_sort | Xiangxing Liu |
| collection | DOAJ |
| description | Background: In recent years, several clinical trials have focused on oncolytic virus (OVs) combined with chemotherapy or immune checkpoint inhibitors (ICIs) in solid tumor patients, which showed encouraging effects. However, few studies have concentrated on the summary on the safety and efficacy of the combined treatments. Therefore, we conducted this meta-analysis to explore the safety and curative effect of the combined therapy.Methods: We searched the PubMed, Cochrane Library, Embase, and Clinicaltrials.gov databases to comprehensively select articles on OVs combined with chemotherapy or ICIs for the solid tumor treatment. Overall survival (OS), progression-free survival (PFS), 1-year survival rate, 2-year survival rate, objective response rate (ORR), and adverse events (AEs) were the outcomes.Results: Fifteen studies with 903 patients were included in this meta-analysis. The pooled ORR was 32% [95% confidence interval (CI): 27–36%, I2 = 24.9%, p = 0.239]. Median OS and median PFS were 6.79 months (CI: 4.29–9.30, I2 = 62.9%, p = 0.044) and 3.40 months (CI: 2.59–4.22, I2 = 0.0%, p = 0.715), respectively. The 1-year survival rate was 38% (CI: 0.29–0.47, I2 = 62.9%, p = 0.044), and the 2-year survival rate was 24% (CI: 12–37%, I2 = 0.0%, p = 0.805). The most common AEs were fever (63%, CI: 57–69%, I2 = 2.3%, p = 0.402), fatigue (58%, CI: 51–65%, I2 = 49.2%, p = 0.096), chill (52%, CI: 43–60%, I2 = 0.0%, p = 0.958), and neutropenia (53%, CI: 47–60%, I2 = 0.0%, p = 0.944).Conclusion: OVs combined with ICIs showed a better efficacy than OVs combined with chemotherapy, which lends support to further clinical trials of OVs combined with ICIs. In addition, OVs combined with pembrolizumab can exert increased safety and efficacy. The toxicity of grades ≥3 should be carefully monitored and observed. However, high-quality, large-scale clinical trials should be completed to further confirm the efficacy and safety of OVs combined with ICIs.Systematic Review Registration: [https://www.crd.york.ac.uk/PROSPERO/login.php], identifier [RD42022348568]. |
| first_indexed | 2024-04-11T15:32:26Z |
| format | Article |
| id | doaj.art-50a78a86c50f46c99ba222f955f409b8 |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-04-11T15:32:26Z |
| publishDate | 2022-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-50a78a86c50f46c99ba222f955f409b82022-12-22T04:16:06ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-11-011310.3389/fphar.2022.10235331023533Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: A meta-analysisXiangxing Liu0Jiaojiao Zhang1Keqing Feng2Simin Wang3Liming Chen4Suping Niu5Qian Lu6Yi Fang7Department of Clinical Pharmacy, Xuzhou Medical University, Xuzhou, ChinaDepartment of Clinical Pharmacy, Xuzhou Medical University, Xuzhou, ChinaDepartment of Clinical Pharmacy, Ocean University of China, Qingdao, ChinaDepartment of Clinical Pharmacy, Xuzhou Medical University, Xuzhou, ChinaNursing Department, Peking University People’s Hospital, Beijing, ChinaClinical Trial Institution, Scientific Research Department, Peking University People’s Hospital, Beijing, ChinaJiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou, ChinaClinical Trial Institution, Peking University People’s Hospital, Beijing, ChinaBackground: In recent years, several clinical trials have focused on oncolytic virus (OVs) combined with chemotherapy or immune checkpoint inhibitors (ICIs) in solid tumor patients, which showed encouraging effects. However, few studies have concentrated on the summary on the safety and efficacy of the combined treatments. Therefore, we conducted this meta-analysis to explore the safety and curative effect of the combined therapy.Methods: We searched the PubMed, Cochrane Library, Embase, and Clinicaltrials.gov databases to comprehensively select articles on OVs combined with chemotherapy or ICIs for the solid tumor treatment. Overall survival (OS), progression-free survival (PFS), 1-year survival rate, 2-year survival rate, objective response rate (ORR), and adverse events (AEs) were the outcomes.Results: Fifteen studies with 903 patients were included in this meta-analysis. The pooled ORR was 32% [95% confidence interval (CI): 27–36%, I2 = 24.9%, p = 0.239]. Median OS and median PFS were 6.79 months (CI: 4.29–9.30, I2 = 62.9%, p = 0.044) and 3.40 months (CI: 2.59–4.22, I2 = 0.0%, p = 0.715), respectively. The 1-year survival rate was 38% (CI: 0.29–0.47, I2 = 62.9%, p = 0.044), and the 2-year survival rate was 24% (CI: 12–37%, I2 = 0.0%, p = 0.805). The most common AEs were fever (63%, CI: 57–69%, I2 = 2.3%, p = 0.402), fatigue (58%, CI: 51–65%, I2 = 49.2%, p = 0.096), chill (52%, CI: 43–60%, I2 = 0.0%, p = 0.958), and neutropenia (53%, CI: 47–60%, I2 = 0.0%, p = 0.944).Conclusion: OVs combined with ICIs showed a better efficacy than OVs combined with chemotherapy, which lends support to further clinical trials of OVs combined with ICIs. In addition, OVs combined with pembrolizumab can exert increased safety and efficacy. The toxicity of grades ≥3 should be carefully monitored and observed. However, high-quality, large-scale clinical trials should be completed to further confirm the efficacy and safety of OVs combined with ICIs.Systematic Review Registration: [https://www.crd.york.ac.uk/PROSPERO/login.php], identifier [RD42022348568].https://www.frontiersin.org/articles/10.3389/fphar.2022.1023533/fullICIsoncolytic virusoncolytic virus combination therapyoncolytic virotherapysingle-arm meta-analysis |
| spellingShingle | Xiangxing Liu Jiaojiao Zhang Keqing Feng Simin Wang Liming Chen Suping Niu Qian Lu Yi Fang Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: A meta-analysis Frontiers in Pharmacology ICIs oncolytic virus oncolytic virus combination therapy oncolytic virotherapy single-arm meta-analysis |
| title | Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: A meta-analysis |
| title_full | Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: A meta-analysis |
| title_fullStr | Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: A meta-analysis |
| title_full_unstemmed | Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: A meta-analysis |
| title_short | Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: A meta-analysis |
| title_sort | efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients a meta analysis |
| topic | ICIs oncolytic virus oncolytic virus combination therapy oncolytic virotherapy single-arm meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2022.1023533/full |
| work_keys_str_mv | AT xiangxingliu efficacyandsafetyofoncolyticviruscombinedwithchemotherapyorimmunecheckpointinhibitorsinsolidtumorpatientsametaanalysis AT jiaojiaozhang efficacyandsafetyofoncolyticviruscombinedwithchemotherapyorimmunecheckpointinhibitorsinsolidtumorpatientsametaanalysis AT keqingfeng efficacyandsafetyofoncolyticviruscombinedwithchemotherapyorimmunecheckpointinhibitorsinsolidtumorpatientsametaanalysis AT siminwang efficacyandsafetyofoncolyticviruscombinedwithchemotherapyorimmunecheckpointinhibitorsinsolidtumorpatientsametaanalysis AT limingchen efficacyandsafetyofoncolyticviruscombinedwithchemotherapyorimmunecheckpointinhibitorsinsolidtumorpatientsametaanalysis AT supingniu efficacyandsafetyofoncolyticviruscombinedwithchemotherapyorimmunecheckpointinhibitorsinsolidtumorpatientsametaanalysis AT qianlu efficacyandsafetyofoncolyticviruscombinedwithchemotherapyorimmunecheckpointinhibitorsinsolidtumorpatientsametaanalysis AT yifang efficacyandsafetyofoncolyticviruscombinedwithchemotherapyorimmunecheckpointinhibitorsinsolidtumorpatientsametaanalysis |